RALGAPB

Across TCGA pan-cancer cohorts, RALGAPB Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated RALGAPB data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher RALGAPB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RALGAPB expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

LUSC, HNSC, and UCEC are the cancer types where RALGAPB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	III,IV	0.113	0.664	<.001	33	view →
HNSC	OS	Median	III,IV	0.213	0.748	.002	27	view →
UCEC	DFS	Median	II,III,IV	0.944	0.300	.004	24	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	IV	0.333	0.671	.048	6	view →
SARC	DFS	Median	All	0.179	0.594	.031	3	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →
COAD	OS	Median	All	1.000	0.791	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RALGAPB–LUSC (DFS)

Open the LUSC breakdown →